Eli Lilly Sees Positive Catalyst with Guidance Boost

3 months ago

Norah Melinda

"Another one out there, Eli Liy is a good one today. Yes, ticker LLY. We're seeing shares of Eli Lilly up a guidance boost here. We are seeing shares up as much as 3.7% right now in trading. This after it raised its full-ear guidance revenue from its weight loss drug and then diabetes drug, this is Mandaro and Zetbound of course. These really having a combined nearly $1.3 billion dollars here in terms of expectations for that and we did see a beat here as we look at these two drugs. So you really are seeing Wall Street coming behind the stock rallying, shares of Eli up about 9% so far this year."

Eli Lilly (LLY) benefits from a guidance boost driven by its weight loss and diabetes drugs, contributing to a current rally with shares up roughly 3.7% in trading and 9% year-to-date as Wall Street rallies behind the beat in expectations.

Related Stocks